From Risk to Reward: Advancing Drug Development for Rare Disease

-

Therapeutic development for rare diseases faces challenges like limited resources, small patient populations, regulatory hurdles, and high costs. This session explores approaches to accelerating progress in rare disease research and therapeutic development through cross-disease collaborations, pooled resource-sharing models, and multi-stakeholder engagement. It will also examine innovative financing approaches and regulatory strategies to help advance rare disease drug development by de-risking development and attracting follow-on investment. Together, these strategies amplify impact, attract more industry participation, and accelerate breakthroughs, advancing treatments for underserved rare disease communities worldwide.

Stay informed by the Milken Institute

    Speakers

    Image

    Terry Jo Bichell

    CEO, COMBINEDBrain
    GC

    Giacomo Chiesi

    Head of Global Rare Diseases, Chiesi Group
    Image

    Adora Ndu

    Chief Regulatory Officer and Executive Vice President of Portfolio Strategy and Management, BridgeBio Pharma
    Image

    Marshall Summar

    CEO, Uncommon Cures

    Tracks